Abstracts tagged "Immune regulation"

Abstract Number: 2858 • 2013 ACR/ARHP Annual Meeting
Inhibition Of Chronic Pain By IL4-10 Synerkine Is Superior To IL-4 Or IL-10 Monotherapy: A Novel Strategy To Restrain Pain In Rheumatic Diseases
Niels Eijkelkamp¹, Sarita Hartgring², Cristine Steen-Louws³, Hanneke Willemen⁴, Qiu-Ling Mao-Ying⁵, Cobi Heijnen⁵, Erik Hack⁶, Annemiek Kavelaars⁵ and J.A.G. van Roon⁷, ¹Laboratory of Neuroimmunology and Developmental Origins of Disease (NIDOD), UMC Utrecht, Utrecht, Netherlands, ²Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³UMC Utrecht, Utrecht, Netherlands, ⁴NIDOD, UMC Utrecht, Utrecht, Netherlands, ⁵MD Anderson Cancer Center, Houston, TX, ⁶Immunology, UMC Utrecht, Utrecht, Netherlands, ⁷Rheumatology & Clinical Immunology/Lab Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Chronic pain is a major problem in many diseases, including RA and OA, arising from inflammation or structural damage. It is often associated with glial…
Abstract Number: 2821 • 2013 ACR/ARHP Annual Meeting
Evaluation Of Selective Manipulation Of The CD28 Co-Stimulation Pathway In The Rhesus Monkey Model Of Collagen-Induced Arthritis
Michel P.M. Vierboom¹, Elia Breedveld¹, Bert 't Hart¹, Flora Coulon² and Bernard Vanhove³, ¹Department of Immunobiology, Biomedical Primate Research Centre, Rijswijk, Netherlands, ²UMR-S 1064, Institut National de la Santé et de la Recherche Médicale, Nantes, France, ³Institut de Transplantation - Urologie - Néphrologie, INSERM UMR-S 1064, Nantes, France
Background/Purpose: T-cells are important in the pathogenesis of rheumatoid arthritis (RA). T-cell activation depends on at least two signals. Next to the first signal that…
Abstract Number: 1843 • 2013 ACR/ARHP Annual Meeting
Treatment With Staphyloccocal Protein A Which Is Immuno-Modulatory In The Murine Collagen Arthritis Model, Does Not Increase Infection Severity In Murine Listeria Or Candida Challenge Models, In Contrast To Anti-TNF Treatment
Edward Bernton¹ and Valerie Lowe², ¹Protalex Inc., Summit, NJ, ²Washington Biotechnology, Inc., Baltimore, MD
Background/Purpose: PRTX-100 is a highly-purified GMP staphylococcal protein A (SpA) that is currently in Phase I trials in patients with active rheumatoid arthritis (RA). SpA…
Abstract Number: 1763 • 2013 ACR/ARHP Annual Meeting
IL4-10 Synerkine: A Novel Immunoregulatory Drug To Prevent Immunopathology In Rheumatic Diseases
Sarita Hartgring¹, Cristine Steen-louws², C.E. Hack³, Martin De Smet⁴, Floris Lafeber⁵ and J.A.G. van Roon⁶, ¹Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology & Clinical Immunology/Lab Translational Immunology, UMC Utrecht, Utrecht, Netherlands, ³Immunology, UMC Utrecht, Utrecht, Netherlands, ⁴Lab Translational Immunology, UMC Utrecht, Utrecht, Netherlands, ⁵Rheumatology & Clinical Immunology, UMC Utrecht, Utrecht, Netherlands, ⁶Rheumatology & Clinical Immunology/Lab Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: A considerable percentage of patients shows a limited response to biologics targeting one specific inflammatory mediator, largely because of redundancy of these mediators. An…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].